<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01331408</url>
  </required_header>
  <id_info>
    <org_study_id>31GC0609</org_study_id>
    <nct_id>NCT01331408</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Efficacy and Safety of Macrolane VRF30 for Volume Restoration and Contouring of the Buttocks</brief_title>
  <official_title>An Open, Post-marketing, Multi-center Study to Evaluate Efficacy and Safety of Macrolane VRF30 for Volume Restoration and Contouring of the Buttocks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Q-Med AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Q-Med AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of Macrolane for volume
      restoration and shaping of the buttocks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Improvement on the Global Esthetic Improvement Scale (GEIS) at Month 6</measure>
    <time_frame>6 Months</time_frame>
    <description>To evaluate the perceived improvement at 6 months compared to baseline as judged by the Subject using Global Esthetic Improvement Scale (GEIS).
Percentage of subjects with improved, much improved or very much improved on GEIS, subject's evaluation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Improvement on the Global Esthetic Improvement Scale (GEIS) at Month 1</measure>
    <time_frame>1 Month</time_frame>
    <description>To evaluate the perceived improvement at 1 month compared to baseline as judged by the Subject using GEIS.
Percentage of subjects with improved, much improved or very much improved on GEIS, subject's evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Improvement on the Global Esthetic Improvement Scale (GEIS) at Month 12</measure>
    <time_frame>12 Months</time_frame>
    <description>To Evaluate the Perceived Improvement at 12 Months Compared to Baseline as Judged by the Subject Using GEIS.
Percentage of subjects with Improved, Much Improved or Very Much Improved on GEIS, Subject's evaluation.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Volume Restoration and Shaping of the Buttocks</condition>
  <arm_group>
    <arm_group_label>Macrolane VRF30</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of Macrolane VRF30 in buttocks</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Macrolane VRF30</intervention_name>
    <description>Injection of Macrolane VRF30 in buttocks. The sum of injected volume of Macrolane VRF30 at initial treatment and touch-up must not exceed 400 ml per Subject</description>
    <arm_group_label>Macrolane VRF30</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 20 years old

          -  willing to undergo augmentation therapy of the buttocks where a maximum total injected
             volume of 400 ml of the study product is judged by the Investigator to be enough to
             achieve full correction

          -  understand and comply with the requirements of the study

          -  be willing to understand and comply with the requirements of the study

          -  be willing to abstain from esthetic surgery and esthetical augmentation procedures
             (other than the study treatment) between the umbilicus and the knees.

          -  be a male or non-pregnant, non breast-feeding female.

          -  give written informed consent to participate in the study

        Exclusion Criteria:

          -  Active skin disease, inflammation or related conditions Tumors or pre-malign tissue
             disorder near or on the area to be treated

          -  scar tissue in the area to be treated

          -  subjects seeking corrections for other body parts then the buttocks anywhere between
             the umbilicus and the knees

          -  subjects with human immunodeficiency virus (HIV) associated lipodystrophy

          -  subjects having undergone liposuction within 6 months prior to inclusion

          -  BMI &lt;20 or expected instable weight

          -  insufficient tissue cover in the area to be treated

          -  excessive skin laxity in the area to be treated

          -  other injectable implant or permanent implant near or in the area to be treated

          -  previous radiation therapy of tumors near or in the area to be treated

          -  concomitant anticoagulant therapy, anti-platelet therapy or a history of bleeding
             disorders.

          -  a presence or history of connective tissue diseases

          -  ongoing immunosuppressive therapy

          -  known allergies or hypersensitivity reactions towards anesthetics

          -  previous inflammatory or hypersensitivity reactions towards products containing
             Hyaluronic acid

          -  any condition which in the opinion of the investigator makes the subject unsuitable
             for inclusion use of any investigational drugs or devices within 30 days prior to
             inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per Hedén, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Akademikliniken, Storängsvägen 10, 115 42 Stockholm, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Artemedis Center for Plastic Surgery</name>
      <address>
        <city>Sint-Denijs-Westrem</city>
        <zip>9051</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Clinico Mir-Mir</name>
      <address>
        <city>Barcelona</city>
        <zip>08006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cirugia Plastica</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademikliniken</name>
      <address>
        <city>Stockholm</city>
        <zip>115 42</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Spain</country>
    <country>Sweden</country>
  </location_countries>
  <results_reference>
    <citation>Camenisch CC, Tengvar M, Hedén P. Macrolane for volume restoration and contouring of the buttocks: magnetic resonance imaging study on localization and degradation. Plast Reconstr Surg. 2013 Oct;132(4):522e-529e. doi: 10.1097/PRS.0b013e31829fe47e.</citation>
    <PMID>24076699</PMID>
  </results_reference>
  <results_reference>
    <citation>De Meyere B, Mir-Mir S, Peñas J, Camenisch CC, Hedén P. Stabilized hyaluronic acid gel for volume restoration and contouring of the buttocks: 24-month efficacy and safety. Aesthetic Plast Surg. 2014 Apr;38(2):404-12. doi: 10.1007/s00266-013-0251-9. Epub 2014 Jan 24.</citation>
    <PMID>24464121</PMID>
  </results_reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>April 5, 2011</study_first_submitted>
  <study_first_submitted_qc>April 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2011</study_first_posted>
  <results_first_submitted>October 16, 2015</results_first_submitted>
  <results_first_submitted_qc>October 17, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 28, 2019</results_first_posted>
  <last_update_submitted>June 12, 2019</last_update_submitted>
  <last_update_submitted_qc>June 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Macrolane VRF30</title>
          <description>Injection of Macrolane VRF30 in buttocks
Macrolane VRF30: Injection of Macrolane VRF30 in buttocks. The sum of injected volume of Macrolane VRF30 at initial treatment and touch-up must not exceed 400 ml per Subject</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intention To Treat</population>
      <group_list>
        <group group_id="B1">
          <title>Macrolane VRF30</title>
          <description>Injection of Macrolane VRF30 in buttocks
Macrolane VRF30: Injection of Macrolane VRF30 in buttocks. The sum of injected volume of Macrolane VRF30 at initial treatment and touch-up must not exceed 400 ml per Subject</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="61"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.3" lower_limit="20.1" upper_limit="64.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Improvement on the Global Esthetic Improvement Scale (GEIS) at Month 6</title>
        <description>To evaluate the perceived improvement at 6 months compared to baseline as judged by the Subject using Global Esthetic Improvement Scale (GEIS).
Percentage of subjects with improved, much improved or very much improved on GEIS, subject's evaluation.</description>
        <time_frame>6 Months</time_frame>
        <population>Intention to treat, subjects with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Macrolane VRF30</title>
            <description>Injection of Macrolane VRF30 in buttocks
Macrolane VRF30: Injection of Macrolane VRF30 in buttocks. The sum of injected volume of Macrolane VRF30 at initial treatment and touch-up must not exceed 400 ml per Subject</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Improvement on the Global Esthetic Improvement Scale (GEIS) at Month 6</title>
          <description>To evaluate the perceived improvement at 6 months compared to baseline as judged by the Subject using Global Esthetic Improvement Scale (GEIS).
Percentage of subjects with improved, much improved or very much improved on GEIS, subject's evaluation.</description>
          <population>Intention to treat, subjects with available data</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.4" lower_limit="67.6" upper_limit="89.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Improvement on the Global Esthetic Improvement Scale (GEIS) at Month 1</title>
        <description>To evaluate the perceived improvement at 1 month compared to baseline as judged by the Subject using GEIS.
Percentage of subjects with improved, much improved or very much improved on GEIS, subject's evaluation.</description>
        <time_frame>1 Month</time_frame>
        <population>Intention to treat, subjects with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Macrolane VRF30</title>
            <description>Injection of Macrolane VRF30 in buttocks
Macrolane VRF30: Injection of Macrolane VRF30 in buttocks. The sum of injected volume of Macrolane VRF30 at initial treatment and touch-up must not exceed 400 ml per Subject</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Improvement on the Global Esthetic Improvement Scale (GEIS) at Month 1</title>
          <description>To evaluate the perceived improvement at 1 month compared to baseline as judged by the Subject using GEIS.
Percentage of subjects with improved, much improved or very much improved on GEIS, subject's evaluation.</description>
          <population>Intention to treat, subjects with available data</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.2" lower_limit="80.7" upper_limit="97.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Improvement on the Global Esthetic Improvement Scale (GEIS) at Month 12</title>
        <description>To Evaluate the Perceived Improvement at 12 Months Compared to Baseline as Judged by the Subject Using GEIS.
Percentage of subjects with Improved, Much Improved or Very Much Improved on GEIS, Subject's evaluation.</description>
        <time_frame>12 Months</time_frame>
        <population>Intention To Treat. Subjects with data available</population>
        <group_list>
          <group group_id="O1">
            <title>Macrolane VRF30</title>
            <description>Injection of Macrolane VRF30 in buttocks
Macrolane VRF30: Injection of Macrolane VRF30 in buttocks. The sum of injected volume of Macrolane VRF30 at initial treatment and touch-up must not exceed 400 ml per Subject</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Improvement on the Global Esthetic Improvement Scale (GEIS) at Month 12</title>
          <description>To Evaluate the Perceived Improvement at 12 Months Compared to Baseline as Judged by the Subject Using GEIS.
Percentage of subjects with Improved, Much Improved or Very Much Improved on GEIS, Subject's evaluation.</description>
          <population>Intention To Treat. Subjects with data available</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.0" lower_limit="53.3" upper_limit="80.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From treatment up to 24 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Macrolane VRF30</title>
          <description>Injection of Macrolane VRF30 in buttocks
Macrolane VRF30: Injection of Macrolane VRF30 in buttocks. The sum of injected volume of Macrolane VRF30 at initial treatment and touch-up must not exceed 400 ml per Subject</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Lipectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Implant Site Pruritus</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Implant Site Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Implant Site Haematoma</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Implant Site Swelling</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication or presentation by PI shall be submitted to Q-Med for review no less than 60 days before submission for publication or presentation. Q-Med will provide any comments to PI within thirty (30) days following receipt of the proposed publication/presentation. PI agree to consider, discuss and give reasonable considerations to comments by Q-Med. Q-Med may also request that the Company name (or that of Q-Med employee) appear or not appear in such publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Medical Affairs</name_or_title>
      <organization>Galderma Uppsala</organization>
      <phone>+46 (0)18 474 9000</phone>
      <email>receptionen.SEUPP@galderma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

